ADMA Biologics Inc $ADMA Shares Purchased by Y Intercept Hong Kong Ltd

Y Intercept Hong Kong Ltd raised its stake in ADMA Biologics Inc (NASDAQ:ADMA) by 40.6% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 105,283 shares of the biotechnology company’s stock after acquiring an additional 30,392 shares during the period. Y Intercept Hong Kong Ltd’s holdings in ADMA Biologics were worth $1,543,000 as of its most recent SEC filing.

Several other institutional investors also recently made changes to their positions in the stock. Homestead Advisers Corp acquired a new stake in ADMA Biologics in the 2nd quarter valued at approximately $1,974,000. American Century Companies Inc. boosted its position in ADMA Biologics by 8.4% during the 2nd quarter. American Century Companies Inc. now owns 4,610,989 shares of the biotechnology company’s stock worth $83,966,000 after acquiring an additional 358,627 shares during the period. Ranger Investment Management L.P. boosted its position in ADMA Biologics by 49.1% during the 2nd quarter. Ranger Investment Management L.P. now owns 2,390,375 shares of the biotechnology company’s stock worth $43,529,000 after acquiring an additional 786,865 shares during the period. Harbor Capital Advisors Inc. bought a new position in shares of ADMA Biologics in the third quarter worth $877,000. Finally, WINTON GROUP Ltd increased its holdings in shares of ADMA Biologics by 302.8% during the second quarter. WINTON GROUP Ltd now owns 272,817 shares of the biotechnology company’s stock valued at $4,968,000 after purchasing an additional 205,094 shares during the period. 75.68% of the stock is owned by institutional investors.

ADMA Biologics Trading Up 1.7%

Shares of ADMA stock opened at $17.30 on Friday. The stock has a 50-day simple moving average of $18.57 and a 200 day simple moving average of $17.04. The stock has a market capitalization of $4.12 billion, a P/E ratio of 20.12 and a beta of 0.47. ADMA Biologics Inc has a fifty-two week low of $13.50 and a fifty-two week high of $25.67. The company has a quick ratio of 3.65, a current ratio of 7.13 and a debt-to-equity ratio of 0.18.

ADMA Biologics (NASDAQ:ADMA) last issued its quarterly earnings results on Wednesday, November 5th. The biotechnology company reported $0.16 EPS for the quarter, hitting the consensus estimate of $0.16. ADMA Biologics had a net margin of 42.87% and a return on equity of 36.52%. The firm had revenue of $134.22 million for the quarter, compared to analysts’ expectations of $131.20 million. During the same period in the previous year, the business earned $0.15 earnings per share. ADMA Biologics’s revenue for the quarter was up 12.0% compared to the same quarter last year. On average, sell-side analysts expect that ADMA Biologics Inc will post 0.51 earnings per share for the current fiscal year.

Analyst Ratings Changes

Separately, Weiss Ratings restated a “hold (c)” rating on shares of ADMA Biologics in a research note on Tuesday, December 23rd. One analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has given a Hold rating to the company’s stock. Based on data from MarketBeat.com, ADMA Biologics presently has an average rating of “Buy” and an average target price of $28.50.

ADMA Biologics Company Profile

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company’s marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.